Min Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min Ren has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Jiahui Liang
Department of Breast Surgery & Department of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, China
3 shared publications- Haisheng Zhou
Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, China
2 shared publications Jing Yang
Department of Breast Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
2 shared publicationsXin Wang
Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
2 shared publicationsChunlin Cai
Department of Pathophysiology, Anhui Medical University, Hefei, China
1 shared publicationDandan Zang
Center for Scientific Research, Anhui Medical University, Hefei, China
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9443
Endocrine Signaling and Tissue Remodeling in Gynecomastia: Implications for Treatment Response
To critically synthesize evidence on treatment response in gynecomastia using a framework that distinguishes biological response, structural response, and patient-important benefit. We searched PubMed, PubMed Central, and targeted journals through 11 September 2026. Priority was given to gynecomastia-specific human studies; evidence from other breast systems, animal models, and general biomarker methodology was treated as indirect. The randomized anastrozole trial showed an endocrine effect but did not demonstrate superiority over placebo on the prespecified structural endpoint. Receptor expression in surgical specimens provides biological plausibility but does not establish receptor functionality, endocrine dependence, or predictive value. Stromal composition may influence lesion regression, but this remains a hypothesis requiring direct testing. Ultrasonography and elastography may support pretreatment characterization, but current studies do not validate imaging features as surrogates for fibrosis or endocrine responsiveness. Gynecomastia-derived organoids offer a disease-relevant model for functional studies, although donor numbers are small and endocrine responsiveness, cellular representativeness, and reproducibility across patients require further evaluation remain uncertain. Biological response, structural response, and patient-important benefit need not occur together or in a fixed sequence. Further research should link tissue and model findings to pretreatment markers, compare treatment benefits, and establish clinical utility before marker-guided care.
- 23 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9443
Open AccessEndocrine Signaling and Tissue Remodeling in Gynecomastia: Implications for Treatment Response
To critically synthesize evidence on treatment response in gynecomastia using a framework that distinguishes biological response, structural response, and patient-important benefit. We searched PubMed, PubMed Central, and targeted journals through 11 September 2026. Priority was given to gynecomastia-specific human studies; evidence from other breast systems, animal models, and general biomarker methodology was treated as indirect. The randomized anastrozole trial showed an endocrine effect but did not demonstrate superiority over placebo on the prespecified structural endpoint. Receptor expression in surgical specimens provides biological plausibility but does not establish receptor functionality, endocrine dependence, or predictive value. Stromal composition may influence lesion regression, but this remains a hypothesis requiring direct testing. Ultrasonography and elastography may support pretreatment characterization, but current studies do not validate imaging features as surrogates for fibrosis or endocrine responsiveness. Gynecomastia-derived organoids offer a disease-relevant model for functional studies, although donor numbers are small and endocrine responsiveness, cellular representativeness, and reproducibility across patients require further evaluation remain uncertain. Biological response, structural response, and patient-important benefit need not occur together or in a fixed sequence. Further research should link tissue and model findings to pretreatment markers, compare treatment benefits, and establish clinical utility before marker-guided care.
- 10 October 2025
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 32 (12) , 1414-1427
GPR107: A key driver of breast cancer invasion and metastasis through collagen IV modulation
Breast cancer is a leading cause of cancer-related death in women, and the development of effective treatments for advanced disease remains a critical challenge. Metastasis, the spread of cancer cells to distant sites, is the major cause of mortality in breast cancer. We identified a novel role for the G protein-coupled receptor 107 (GPR107) in promoting breast cancer invasion and metastasis. Furthermore, we found that GPR107 mediates a reduction in collagen Ⅳ (COL4), a key component of the extracellular matrix (ECM) that normally restricts tumor cell invasion. This reduction in COL4 levels was associated with GPR107 mediating the Clathrin-mediated endocytosis of COL4 from the ECM, an increase in matrix metalloproteinase 2 (MMP2) production to degrade COL4 in the ECM, and a decrease in COL4 production. Mechanistically, we identified GPR107 as a key mediator of the ERK/STAT3 pathway activation through β-arrestin, leading to increased expression of MMP2 and suppression of COL4 gene transcription, effectively promoting invasion and metastasis in breast cancer cells. These findings suggest that GPR107 could serve as a promising biomarker for predicting breast cancer malignancy and a potential therapeutic target for preventing and treating metastatic disease.
- 10 October 2025
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 32 (12) , 1414-1427
GPR107: A key driver of breast cancer invasion and metastasis through collagen IV modulation
Breast cancer is a leading cause of cancer-related death in women, and the development of effective treatments for advanced disease remains a critical challenge. Metastasis, the spread of cancer cells to distant sites, is the major cause of mortality in breast cancer. We identified a novel role for the G protein-coupled receptor 107 (GPR107) in promoting breast cancer invasion and metastasis. Furthermore, we found that GPR107 mediates a reduction in collagen Ⅳ (COL4), a key component of the extracellular matrix (ECM) that normally restricts tumor cell invasion. This reduction in COL4 levels was associated with GPR107 mediating the Clathrin-mediated endocytosis of COL4 from the ECM, an increase in matrix metalloproteinase 2 (MMP2) production to degrade COL4 in the ECM, and a decrease in COL4 production. Mechanistically, we identified GPR107 as a key mediator of the ERK/STAT3 pathway activation through β-arrestin, leading to increased expression of MMP2 and suppression of COL4 gene transcription, effectively promoting invasion and metastasis in breast cancer cells. These findings suggest that GPR107 could serve as a promising biomarker for predicting breast cancer malignancy and a potential therapeutic target for preventing and treating metastatic disease.
- Open Access
- 15 November 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1198826
Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer
Introduction: Breast cancer (BC) is now the most common type of cancer in women. Disulfidptosis is a new regulation of cell death (RCD). RCD dysregulation is causally linked to cancer. However, the comprehensive relationship between disulfidptosis and BC remains unknown. This study aimed to explore the predictive value of disulfidptosis-related genes (DRGs) in BC and their relationship with the TME.Methods: This study obtained 11 disulfidptosis genes (DGs) from previous research by Gan et al. RNA sequencing data of BC were downloaded from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus database (GEO) databases. First, we examined the effect of DG gene mutations and copy number changes on the overall survival of breast cancer samples. We then used the expression profile data of 11 DGs and survival data for consensus clustering, and BC patients were divided into two clusters. Survival analysis, gene set variation analysis (GSVA) and ss GSEA were used to compare the differences between them. Subsequently, DRGs were identified between the clusters used to perform Cox regression and least absolute shrinkage and selection operator regression (LASSO) analyses to construct a prognosis model. Finally, the immune cell infiltration pattern, immunotherapy response, and drug sensitivity of the two subtypes were analyzed. CCK-8 and a colony assay obtained by knocking down genes and gene sequencing were used to validate the model.Result: Two DG clusters were identified based on the expression of 11DGs. Then, 225 DRGs were identified between them. RS, composed of six genes, showed a significant relationship with survival, immune cell infiltration, clinical characteristics, immune checkpoints, immunotherapy response, and drug sensitivity. Low-RS shows a better prognosis and higher immunotherapy response than high-RS. A nomogram with perfect stability constructed using signature and clinical characteristics can predict the survival of each patient. CCK-8 and colony assay obtained by knocking down genes have demonstrated that the knockdown of high-risk genes in the RS model significantly inhibited cell proliferation.Discussion: This study elucidates the potential relationship between disulfidptosis-related genes and breast cancer and provides new guidance for treating breast cancer.
- 15 November 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1198826
Open AccessIdentification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer
Introduction: Breast cancer (BC) is now the most common type of cancer in women. Disulfidptosis is a new regulation of cell death (RCD). RCD dysregulation is causally linked to cancer. However, the comprehensive relationship between disulfidptosis and BC remains unknown. This study aimed to explore the predictive value of disulfidptosis-related genes (DRGs) in BC and their relationship with the TME.Methods: This study obtained 11 disulfidptosis genes (DGs) from previous research by Gan et al. RNA sequencing data of BC were downloaded from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus database (GEO) databases. First, we examined the effect of DG gene mutations and copy number changes on the overall survival of breast cancer samples. We then used the expression profile data of 11 DGs and survival data for consensus clustering, and BC patients were divided into two clusters. Survival analysis, gene set variation analysis (GSVA) and ss GSEA were used to compare the differences between them. Subsequently, DRGs were identified between the clusters used to perform Cox regression and least absolute shrinkage and selection operator regression (LASSO) analyses to construct a prognosis model. Finally, the immune cell infiltration pattern, immunotherapy response, and drug sensitivity of the two subtypes were analyzed. CCK-8 and a colony assay obtained by knocking down genes and gene sequencing were used to validate the model.Result: Two DG clusters were identified based on the expression of 11DGs. Then, 225 DRGs were identified between them. RS, composed of six genes, showed a significant relationship with survival, immune cell infiltration, clinical characteristics, immune checkpoints, immunotherapy response, and drug sensitivity. Low-RS shows a better prognosis and higher immunotherapy response than high-RS. A nomogram with perfect stability constructed using signature and clinical characteristics can predict the survival of each patient. CCK-8 and colony assay obtained by knocking down genes have demonstrated that the knockdown of high-risk genes in the RS model significantly inhibited cell proliferation.Discussion: This study elucidates the potential relationship between disulfidptosis-related genes and breast cancer and provides new guidance for treating breast cancer.
- 25 September 2023
- Published by Wiley in Microsurgery
- Vol. 43 (8) , 809-817
Contralateral internal mammary artery perforator flap for large inner chest wall defect repair and immediate breast reconstruction after excision of large malignant inner breast tumors
ObjectivesLarge breast tumor resection can cause chest wall defects that are difficult to close. A combination of oncoplastic techniques is required to repair chest wall defects and immediately reconstruct the breast. In this report, we present the use of the contralateral internal mammary artery perforator (IMAP) flap to repair large chest wall defects and perform breast reconstruction for a series of patients.MethodsBetween July 2013 and June 2020, 10 patients and 4 patients underwent chest wall defect repair and breast reconstruction, respectively, with contralateral IMAP flaps. The average body mass index was 26.9 kg/m2 (range: 21.5-33.7 kg/m2). Tumor sizes varied from 2.5 x 1.5 x 0.8 to 9.5 x 6.0 x 4.0 cm3. Defect sizes ranged from 16 x 10 to 8 x 4 cm2. All patients underwent multiple imaging examinations to exclude abnormalities. Primary outcomes included complete tumor resection and flap survival. Secondary outcomes included the BREAST-Q results and bilateral breast symmetry measurements.ResultsAll flaps exhibited good postoperative survival and were between 20 x 12 and 10 x 5 cm2. Two patients experienced minor complications that did not influence outcomes. No obvious donor site complications were observed. The BREAST-Q results indicated favorable reconstructive efficacy, with "satisfaction with breasts," "physical well-being (chest)," and "satisfaction with the outcome" scores of 77.8 (range: 58-87), 83.2 (range: 77-89), and 80.1 (range: 70-88), respectively. No signs of tumor recurrence were observed during a median follow-up period of 53.5 months (range: 6-83 months). However, poor postoperative bilateral breast symmetry was observed (vertical extent: 0.63 [range: 0.36-0.88]; horizontal extent: 0.64 [range: 0.41-0.80]).ConclusionsIMAP flaps are reliable options for chest wall defect repair and breast reconstruction for selected patients with locally advanced breast cancer and inner breast tumors. Despite poor postoperative bilateral breast symmetry, most patients reported excellent outcomes.
- 25 September 2023
- Published by Wiley in Microsurgery
- Vol. 43 (8) , 809-817
Contralateral internal mammary artery perforator flap for large inner chest wall defect repair and immediate breast reconstruction after excision of large malignant inner breast tumors
ObjectivesLarge breast tumor resection can cause chest wall defects that are difficult to close. A combination of oncoplastic techniques is required to repair chest wall defects and immediately reconstruct the breast. In this report, we present the use of the contralateral internal mammary artery perforator (IMAP) flap to repair large chest wall defects and perform breast reconstruction for a series of patients.MethodsBetween July 2013 and June 2020, 10 patients and 4 patients underwent chest wall defect repair and breast reconstruction, respectively, with contralateral IMAP flaps. The average body mass index was 26.9 kg/m2 (range: 21.5-33.7 kg/m2). Tumor sizes varied from 2.5 x 1.5 x 0.8 to 9.5 x 6.0 x 4.0 cm3. Defect sizes ranged from 16 x 10 to 8 x 4 cm2. All patients underwent multiple imaging examinations to exclude abnormalities. Primary outcomes included complete tumor resection and flap survival. Secondary outcomes included the BREAST-Q results and bilateral breast symmetry measurements.ResultsAll flaps exhibited good postoperative survival and were between 20 x 12 and 10 x 5 cm2. Two patients experienced minor complications that did not influence outcomes. No obvious donor site complications were observed. The BREAST-Q results indicated favorable reconstructive efficacy, with "satisfaction with breasts," "physical well-being (chest)," and "satisfaction with the outcome" scores of 77.8 (range: 58-87), 83.2 (range: 77-89), and 80.1 (range: 70-88), respectively. No signs of tumor recurrence were observed during a median follow-up period of 53.5 months (range: 6-83 months). However, poor postoperative bilateral breast symmetry was observed (vertical extent: 0.63 [range: 0.36-0.88]; horizontal extent: 0.64 [range: 0.41-0.80]).ConclusionsIMAP flaps are reliable options for chest wall defect repair and breast reconstruction for selected patients with locally advanced breast cancer and inner breast tumors. Despite poor postoperative bilateral breast symmetry, most patients reported excellent outcomes.
- 1 February 2022
- Published by Wiley in The Journal of Gene Medicine
- Vol. 24 (5) , e3413
The lncRNA HOXA11‐AS acts as a tumor promoter in breast cancer through regulation of the miR‐125a‐5p/TMPRSS4 axis
Background: Long non‐coding RNAs (lncRNAs) play vital roles in tumorigenesis. Here, we explored how lncRNA HOXA11‐AS functions in the progression of breast cancer (BC).Methods: HOXA11‐AS and miR‐125a‐5p levels were measured by a quantitative real‐time polymerase chain reaction, whereas western blotting determined TMPRSS4 levels in BC tumor tissues, adjacent normal tissues and BC cell lines. The roles of HOXA11‐AS, miR‐125a‐5p and TMPRSS4 in BC proliferation were investigated using cell counting kit‐8, colony formation and flow cytometry assays, whereas scratch and transwell assays were used to measure metastasis. RNA pull‐down assays and dual‐luciferase assays assessed direct interactions between HOXA11‐AS and miR‐125a‐5p. The effects of HOXA11‐AS in vivo were investigated in a BC xenograft model.Results: HOXA11‐AS was upregulated in tumor tissues of 56 BC patients compared to adjacent non‐tumor tissues, with high levels being associated with worse overall survival. Silencing of HOXA11‐AS inhibited the proliferation and metastasis of BC cells, leading to cell cycle arrest in G0/G1 and induction of apoptosis. We identified miR‐125a‐5p as a target of HOXA11‐AS, with miR‐125a‐5p inhibitors partially restoring the reduction of cell proliferation and metastasis induced by HOXA11‐AS silencing. We also determined that miR‐125a‐5p targeted TMPRSS4 mRNA, with HOXA11‐AS knockdown and miR‐125a‐5p mimics suppressing TMPRSS4. Overexpression of TMPRSS4 partially compensated for the reduction of cell proliferation and metastasis induced by HOXA11‐AS silencing. Finally, we confirmed the mechanism of HOXA11‐AS in the regulation of tumorigenesis in the mouse model.Conclusions: HOXA11‐AS regulates the tumorigenic ability of BC via the miR‐125a‐5p/TMPRSS4 axis. This provides insights for regulatory mechanisms involved in BC progression, and may enable new treatment strategies in the clinical setting.
- 1 February 2022
- Published by Wiley in The Journal of Gene Medicine
- Vol. 24 (5) , e3413
The lncRNA HOXA11‐AS acts as a tumor promoter in breast cancer through regulation of the miR‐125a‐5p/TMPRSS4 axis
Background: Long non‐coding RNAs (lncRNAs) play vital roles in tumorigenesis. Here, we explored how lncRNA HOXA11‐AS functions in the progression of breast cancer (BC).Methods: HOXA11‐AS and miR‐125a‐5p levels were measured by a quantitative real‐time polymerase chain reaction, whereas western blotting determined TMPRSS4 levels in BC tumor tissues, adjacent normal tissues and BC cell lines. The roles of HOXA11‐AS, miR‐125a‐5p and TMPRSS4 in BC proliferation were investigated using cell counting kit‐8, colony formation and flow cytometry assays, whereas scratch and transwell assays were used to measure metastasis. RNA pull‐down assays and dual‐luciferase assays assessed direct interactions between HOXA11‐AS and miR‐125a‐5p. The effects of HOXA11‐AS in vivo were investigated in a BC xenograft model.Results: HOXA11‐AS was upregulated in tumor tissues of 56 BC patients compared to adjacent non‐tumor tissues, with high levels being associated with worse overall survival. Silencing of HOXA11‐AS inhibited the proliferation and metastasis of BC cells, leading to cell cycle arrest in G0/G1 and induction of apoptosis. We identified miR‐125a‐5p as a target of HOXA11‐AS, with miR‐125a‐5p inhibitors partially restoring the reduction of cell proliferation and metastasis induced by HOXA11‐AS silencing. We also determined that miR‐125a‐5p targeted TMPRSS4 mRNA, with HOXA11‐AS knockdown and miR‐125a‐5p mimics suppressing TMPRSS4. Overexpression of TMPRSS4 partially compensated for the reduction of cell proliferation and metastasis induced by HOXA11‐AS silencing. Finally, we confirmed the mechanism of HOXA11‐AS in the regulation of tumorigenesis in the mouse model.Conclusions: HOXA11‐AS regulates the tumorigenic ability of BC via the miR‐125a‐5p/TMPRSS4 axis. This provides insights for regulatory mechanisms involved in BC progression, and may enable new treatment strategies in the clinical setting.